Patrick Hsu

Patrick Hsu, co-founder of Arc Institute and a pioneer in genome editing and CRISPR technologies, shares insights on merging AI with biology. He discusses Evo 2, a groundbreaking model that analyzes genomic data to identify disease-causing mutations and design new biological systems. Patrick highlights the transformative potential of AI in drug discovery, emphasizing collaboration between academia and industry. He also explores the gut-brain connection and advocates for holistic health approaches, illustrating how AI can personalize medicine and enhance wellness.

In this engaging discussion, Nima Alidoust, CEO of Vevo Therapeutics, and Patrick Hsu, CEO of the Arc Institute, dive into the revolutionary Tahoe-100M dataset that is reshaping drug discovery. They explore the fascinating potential of virtual cell models and AI in understanding disease behaviors at a cellular level. The conversation highlights challenges in data collection and the critical need for high-quality datasets in biomedical research. They also discuss the importance of open-sourcing data to foster collaboration and innovation in the biotech field.

Tyler Cowen, an economics professor, shares insights alongside Patrick Hsu, co-founder of the Arc Institute, and Adam Marblestone, CEO of Convergent Research. They explore the transformative power of new funding models like Fast Grants and Flexible Research Organizations, emphasizing their role in fostering innovation. The conversation also highlights the necessity for evolving scientific practices in response to modern challenges, particularly how startup culture invigorates research. They discuss the collaboration needed in life sciences and the impact of AI on scientific breakthroughs.